A review published on April 5th raises concerns about the modification of mRNA in COVID-19 vaccines and its potential contribution to immune suppression and cancer development. The modification, known as N1-methyl-pseudouridine (m1-psi), is used to prevent degradation of mRNA by the immune system when injected. Researchers argue that this modification may reduce immune responses and promote cancer in susceptible individuals.
The review highlights that modified RNA stimulates different responses in the body compared to natural RNA. Modified RNA tends to produce more aberrant proteins, potentially contributing to cell genome instability. It also induces a milder immune response and is associated with immune chemicals that promote tolerance of foreign RNA injections. In contrast, natural RNA stimulates the activity of key anti-tumor substances and other immune chemicals.
The review authors cite a study in mice with melanoma as evidence. When injected with natural RNA, the mice had a more robust immune response and a higher survival rate compared to those injected with modified RNA. The study suggests that complete mRNA modification reduced survival in recipients.
However, the senior author of the mentioned study in mice argues that their results were taken out of context and that modified mRNA does not promote